Therefore, both stimulating the release of membrane-bound EpFAs in conjunction with sEH enzymatic activity inhibition represents a viable approach to exploit the compensatory increase in CYP2J2 metabolic activity and delay the degradation of the protective EpFAs produced in the DCM heart. Here, CYP2J2 is linked to familial dilated cardiomyopathy.